A Product and Pipeline Analysis of the Human Plasma-derived Therapeutics Market

Launch of Novel Immunoglobulin Products and Increasing Awareness of Therapeutic Options to Drive Double-digit Market Growth

USD 6,000.00

* Required Fields

USD 6,000.00


Be the first to review this product

The global human plasma-derived therapeutics market is expected to experience a surge in demand due to an increase in the awareness of diseases and therapeutic options. The plasma-derived therapeutics market is segmented into albumin, immunoglobulins, coagulation factors, and other haemotologicals. The segments are discussed with supporting information on clinical trial timelines and results and historical and projected launch timelines. The report also focuses on the competitive landscape of both marketed and pipeline products and provides the market drivers and challenges.

Table of Contents

Executive SummaryExecutive SummaryRecent Market DevelopmentsKey M&As and Partnership AssessmentCompanies to WatchMethodology and ScopeMethodology and ScopeMarket BackgroundMarket Background—SegmentationMarket Background—Segmentation (continued)Market Background—Segmentation (continued)Market SegmentationMarket Segmentation (continued)Market ForecastingCompetitive LandscapeCompetitive Landscape—Human Plasma-derived Therapeutics: Marketed ProductsCompetitive Landscape—Human Plasma-derived Therapeutics Market: Pipeline ProductsCompetitive Landscape—Count of Marketed and Pipeline ProductsCompetitive Landscape—Key Clinical TrialsMarketed Product AnalysisMarketed Products Synopsis—AlbuminMarketed Products Synopsis—Other HaematologicalsMarketed Products Synopsis—Other Haematologicals (continued)Marketed Products Synopsis—Coagulation Factors Marketed Products Synopsis—Coagulation Factors (continued) Marketed Products Synopsis—Coagulation Factors (continued) Marketed Products Synopsis—Coagulation Factors (continued) Marketed Products Synopsis—ImmunoglobulinsMarketed Products Synopsis—Immunoglobulins (continued)Marketed Products Synopsis—Immunoglobulins (continued)Marketed Products Synopsis—Immunoglobulins (continued)Marketed Products Synopsis—Immunoglobulins (continued)Marketed Products Synopsis—Immunoglobulins (continued)Pipeline Product AnalysisPipeline Analysis—ApprovedPipeline Analysis—Phase 3Pipeline Analysis—Phase 3 (continued)Pipeline Analysis—Phase 2Pipeline Analysis—Phase 1Product DashboardProduct Dashboard—ResusixTM, Entegrion, Inc.Product Dashboard—CINRYZE® (new formulation), ShireProduct Dashboard—BIOSTATE® (new formulation), CSL BehringProduct Dashboard—Gammagard, BaxterConclusions and RecommendationsConclusions and RecommendationsLegal DisclaimerAppendixPlasma—OverviewPlasma—Overview (continued)The Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition—Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.